Entrada Therapeutics (NASDAQ:TRDA) Stock Price Down 4.8% – Should You Sell?

Entrada Therapeutics, Inc. (NASDAQ:TRDA) shares traded down 4.8% on Friday . The stock traded as low as $9.99 and last traded at $10.02. 101,589 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 165,623 shares. The stock had previously closed at $10.52.

Analysts Set New Price Targets

A number of equities analysts have weighed in on TRDA shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Monday, December 29th. Roth Capital set a $13.00 price target on shares of Entrada Therapeutics in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $16.50.

Entrada Therapeutics Stock Performance

The firm has a market cap of $382.96 million, a P/E ratio of -4.02 and a beta of -0.12. The firm has a 50 day simple moving average of $9.72 and a 200 day simple moving average of $7.32.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Entrada Therapeutics had a negative net margin of 168.16% and a negative return on equity of 26.42%. The company had revenue of $1.61 million for the quarter, compared to the consensus estimate of $8.62 million. Sell-side analysts predict that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Insider Activity

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 8,910 shares of the firm’s stock in a transaction on Friday, November 21st. The shares were sold at an average price of $9.98, for a total value of $88,921.80. Following the completion of the transaction, the chief financial officer directly owned 110,026 shares of the company’s stock, valued at $1,098,059.48. This trade represents a 7.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bros. Advisors Lp Baker purchased 100,736 shares of Entrada Therapeutics stock in a transaction dated Wednesday, November 12th. The shares were purchased at an average price of $7.76 per share, with a total value of $781,711.36. Following the completion of the transaction, the insider directly owned 4,664,924 shares in the company, valued at approximately $36,199,810.24. This represents a 2.21% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 178,044 shares of company stock valued at $1,352,568 and have sold 408,910 shares valued at $3,608,922. 8.11% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. State of Wyoming raised its holdings in shares of Entrada Therapeutics by 130.9% in the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after acquiring an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new position in shares of Entrada Therapeutics in the second quarter worth approximately $68,000. IHT Wealth Management LLC bought a new position in shares of Entrada Therapeutics in the second quarter worth approximately $72,000. Finally, Trexquant Investment LP purchased a new stake in Entrada Therapeutics in the first quarter valued at approximately $101,000. 86.39% of the stock is currently owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.